03/08/21 1:00 AMNYSE : RO, ROG, RHHBYGenentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder CancerGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is voluntarily withdrawing the U.S. indication for Tecentriq (R) (atezolizumab) in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer). This decision was made in consultationRHEA-AIvery positive
03/04/21 5:42 PMNYSE : RO, ROG, RHHBYGenentech's Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating ConditionGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Actemra (R) (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associatedRHEA-AIneutral
03/01/21 3:00 PMNYSE : ROGRogers Releases Inaugural Environmental, Social and Governance ReportRogers Corporation (NYSE:ROG) announced today the release of its 2021 ESG Report, which details the Company's environmental, social and governance (ESG) strategies and commitments."I am pleased to introduce Rogers' first ESG Report," stated Bruce D. Hoechner, Rogers' President and CEO. "ThisRHEA-AIneutral
02/24/21 5:00 PMNYSE : RHHBY, RO, ROGGenentech Announces Results From Evrysdi (risdiplam) Study in Infants With Type 1 Spinal Muscular Atrophy (SMA) Published in New England Journal of Medicine Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Evrysdi(TM) (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA) were published in the February 24, 2021 online issue of theRHEA-AIneutral
02/18/21 4:09 PMNYSE : ROGRogers Corporation Reports Fourth Quarter and Full Year 2020 ResultsRogers Corporation (NYSE:ROG) today announced financial results for the full year and fourth quarter of 2020."Accelerating growth in Advanced Mobility markets, combined with continued improvements in operational execution, drove fourth quarter results above the top end of our guidance," statedRHEA-AIneutral
02/18/21 4:07 PMNYSE : ROGRogers Corporation Announces Retirement of Chief Financial OfficerRogers Corporation (NYSE:ROG) announced today that Michael M. Ludwig, Senior Vice President, Chief Financial Officer and Treasurer, intends to retire from the Company in 2021. Mr. Ludwig has not given notice of a specific retirement date and he intends to continue in his role until his successor isRHEA-AIneutral
02/12/21 1:00 AMNYSE : RO, ROG, RHHBYNew Phase III Data Show Genentech's Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for PatientsGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or "wet" age-related macular degeneration (nAMD).RHEA-AIvery positive
02/10/21 9:15 AMNYSE : ROGRogers Corporation Reports Fire in S. Korea PlantRogers Corporation (NYSE:ROG) reports that there was a fire at its UTIS manufacturing facility in Ansan, S. Korea on Tuesday, February 9, 2021, at approximately 9 p.m. local time. The site was safely evacuated and there were no reported injuries; however, there is extensive damage to theRHEA-AIneutral
02/04/21 4:30 PMNYSE : ROGRogers Schedules Q4 & Full Year 2020 Earnings Call for February 18, 2021Rogers Corporation (NYSE:ROG) plans to announce fourth quarter and full year 2020 results on February 18 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Bruce Hoechner, President and CEO, who will be joined by Mike Ludwig, SVP and CFO, andRHEA-AIneutral
01/25/21 1:00 AMNYSE : RO, ROG, RHHBYGenentech's Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular DegenerationGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with neovascular or "wet"RHEA-AIneutral
